In:
Oncology, S. Karger AG, Vol. 64, No. 1 ( 2003), p. 28-35
Abstract:
〈 i 〉 Objective: 〈 /i 〉 Paclitaxel-cisplatin is considered to be a standard therapy for metastatic non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the activity and toxicity of this combination with vinorelbine or gemcitabine as front-line therapy in brain metastases from NSCLC. 〈 i 〉 Methods: 〈 /i 〉 Twenty-six chemotherapy-naive patients with an ECOG performance status of 0–2 were treated with paclitaxel (135 mg/m 〈 sup 〉 2 〈 /sup 〉 ) on day 1, cisplatin (120 mg/m 〈 sup 〉 2 〈 /sup 〉 ) on day 1, and either vinorelbine (30 mg/m 〈 sup 〉 2 〈 /sup 〉 ) on days 1 and 15 or gemcitabine (800 mg/m 〈 sup 〉 2 〈 /sup 〉 ) on days 1 and 8. Whole-brain irradiation was offered early in case of progression and later as consolidation treatment. 〈 i 〉 Results: 〈 /i 〉 All patients were evaluated for toxicity and 25 for response. An intracranial response rate was observed in 38% of the patients (95% CI: 22–59%). WHO grade 3–4 neutropenia and thrombocytopenia occurred in 31 and 4% of the patients, respectively. There was one treatment-related death. Non-hematological toxicities were mild. After a median follow-up of 46 months, the median overall survival for all patients was 21.4 weeks and the median time to progression was 12.8 weeks. 〈 i 〉 Conclusions: 〈 /i 〉 Paclitaxel and cisplatin combined with vinorelbine or gemcitabine as front-line therapy in brain metastases seem to achieve responses similar to those for extracranial disease, suggesting a meaningful role in this setting.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2003
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6